Tiziana Life Sciences : StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort - Form 6-K - Marketscreener.com
3/1/2022 12:00:00 AM4 yearsago
by MarketScreener
by MarketScreener
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort New York, March 1, 2022 - Tiziana Life Sciences Ltd.'s former subsidiary, AccuStem Sciences, Inc. , today... | March 3, 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort New York, March 1, 2022 - Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (fo… [+4560 chars]
full article...